Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tavilermide

Next Previous
X
Search
Drug Profile

Tavilermide

Alternative Names: MIM-D3

Latest Information Update: 18 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mimetogen Pharmaceuticals
  • Class Amides; Aza compounds; Cyclic ethers; Eye disorder therapies; Neuroprotectants; Nitrobenzoates; Small molecules
  • Mechanism of Action TrkA receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Dry eyes
  • No development reported Glaucoma

Most Recent Events

  • 11 May 2024 Mimetogen Pharmaceuticals completes a phase III trial in Dry eyes (Ophthalmic, Liquid) in USA (NCT05848128)
  • 28 Jun 2023 Mimetogen Pharmaceuticals initiates a phase III trial for Dry eyes (Ophthalmic) in USA (NCT05848128)
  • 11 May 2023 Mimetogen Pharmaceuticals plans a phase III trial for dry eyes (Opthalmic, Liquid) in May 2023 (NCT05848128)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top